Joaquin Mateo, MD PhD, is a physician-scientist working in precision medicine and advanced prostate cancer. He received his MD from the University of Barcelona in 2006 and pursued his medical training in Oncology at the Catalan Institute of Oncology (Barcelona). Next, he completed a fellowship in early-phase clinical trials at the Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research (London) in 2011 under the mentorship of Prof. Johann de Bono and Prof. Stan Kaye, working in first-in-man clinical trials of several PARP inhibitors and compounds targeting the PI3K-AKT-mTOR pathway.

Starting in 2013, Dr. Mateo progressively directed his focus towards designing and developing clinical trials for advanced prostate cancer, with a particular emphasis on the development of PARP inhibitors for molecularly-defined subsets of the disease. His studies on the genomic characterisation of advanced prostate cancer formed the basis of his PhD in Cancer Genomics, awarded by the University of London in 2017. His work in this area earned him a Prostate Cancer Foundation Young Investigator Award.

In late 2017, Dr. Mateo was recruited as a Group Leader at the Vall d’Hebron Institute of Oncology (VHIO, Barcelona). In this role, he leads a laboratory team dedicated to advancing personalised therapeutic approaches to advanced prostate cancer. Simultaneously, he serves as a medical oncologist at the Vall d’Hebron University Hospital on the same campus, leading several academic and industry-sponsored clinical trials.

Furthermore, in 2017, Dr. Mateo joined the ESMO Translational Research and Precision Medicine Working Group, actively contributing to the development of various educational resources and recommendation documents for facilitating and harmonising implementation of cancer genomics data into clinical decision-making, such as the ESCAT scale. He was the Chair of the Working Group between 2020 and 2023.